MedTrace Logo

Using Autologous Platelet Rich Plasma (PRP) Gel to Treat Deep 2nd and 3rd Degree Burns

NCT01843686 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2018-01-09

No results posted yet for this study

Summary

This study will demonstrate the safety of the application of autologous platelet rich plasma (PRP) gel following excision and autologous skin grafting of acute deep 2nd and 3rd degree burns. The study will be a randomized, double-blinded controlled safety study. Investigators expect that the PRP will deliver improved hemostasis and growth factors at the wound site thus increasing the effectiveness of treatment at the wound site. This will lead to rapid production and delivery of an autologous therapy that should minimize additional morbidity to the patient.

Conditions

  • Acute Burns

Interventions

DEVICE

Magellan®

Autologous Platelet Rich Plasma Prepared Using the Magellan System

OTHER

Placebo Saline Gel and Usual and Customary Standard of Care

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Arteriocyte, Inc.

    lead INDUSTRY

Principal Investigators

  • Brian R. Barnes, PhD · Arteriocyte, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
86 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2018-02-28
Completion
2018-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01843686 on ClinicalTrials.gov